Damien Albin Douarre @Lyssky: "🔔 𝐄𝐚𝐫𝐧𝐢𝐧𝐠 𝐜𝐚𝐥𝐥 - $𝐉𝐍𝐉 Q1..."

France

🔔 𝐄𝐚𝐫𝐧𝐢𝐧𝐠 𝐜𝐚𝐥𝐥 - $𝐉𝐍𝐉 Q1 2026 earnings season kicks off for our portfolio with Johnson & Johnson, and it’s a solid start. Results came in slightly above expectations, though without any major surprises. Revenue grew 9.9% year-over-year to $24.1B (vs. $23.63B expected), while adjusted EPS landed at $2.70, above the $2.66 consensus despite a modest decline. Performance was driven by strong momentum across both segments: 🔹Innovative Medicine sales up 11.2% globally 🔹MedTech growing at 7.7% Digging deeper into Innovative Medicine, growth was led by: 🔹Oncology: +22.8% 🔹Neuroscience: +32% Looking ahead, 2026 guidance has been revised upward for both operational sales and adjusted EPS. Operating income and net income remain stable, reflecting heavier investment in the first half of the year. Overall, a positive quarter. The business continues to execute as expected, with strong underlying trends in oncology and neuroscience confirming the strength of the investment case, even in a more uncertain macro environment. That said, current valuation levels don’t justify adding to the position at this stage. The thesis remains intact, but discipline on price matters most. Cheers 🥂 D.A.D $SPX500 $NSDQ100 $DJ30 𝘋𝘪𝘴𝘤𝘭𝘢𝘪𝘮𝘦𝘳: 𝘛𝘩𝘪𝘴 𝘱𝘰𝘴𝘵 𝘳𝘦𝘧𝘭𝘦𝘤𝘵𝘴 𝘮𝘺 𝘱𝘦𝘳𝘴𝘰𝘯𝘢𝘭 𝘰𝘱𝘪𝘯𝘪𝘰𝘯𝘴 𝘢𝘯𝘥 𝘪𝘯𝘷𝘦𝘴𝘵𝘮𝘦𝘯𝘵 𝘥𝘦𝘤𝘪𝘴𝘪𝘰𝘯𝘴. 𝘐𝘵 𝘪𝘴 𝘯𝘰𝘵 𝘧𝘪𝘯𝘢𝘯𝘤𝘪𝘢𝘭 𝘢𝘥𝘷𝘪𝘤𝘦. 𝘐𝘯𝘷𝘦𝘴𝘵𝘪𝘯𝘨 𝘪𝘯𝘷𝘰𝘭𝘷𝘦𝘴 𝘳𝘪𝘴𝘬, 𝘢𝘯𝘥 𝘱𝘢𝘴𝘵 𝘱𝘦𝘳𝘧𝘰𝘳𝘮𝘢𝘯𝘤𝘦 𝘪𝘴 𝘯𝘰𝘵 𝘪𝘯𝘥𝘪𝘤𝘢𝘵𝘪𝘷𝘦 𝘰𝘧 𝘧𝘶𝘵𝘶𝘳𝘦 𝘳𝘦𝘴𝘶𝘭𝘵𝘴.

Not investment advice. The author may have financial interests in the mentioned instruments.

3 Mentioned

SPX500

SPX500 Index (Non Expiry)

NSDQ100

NASDAQ100 Index (Non Expiry)

DJ30

DJ30 Index (Non Expiry)

Strictly Necessary Cookies

Performance Cookies

Functional Cookies

Targeting Cookies